title: Thrombolytic therapy of acute ischemic stroke: correlation of angiographic recanalization with clinical outcome.
abstract: OBJECTIVE
  The effect of vessel patency, following recombinant tissue plasminogen activator (rtPA) administration, on clinical outcome in acute ischemic stroke (AIS) has been controversial. We studied the effect of recanalization following intraarterial (IA) and intravenous/IA (IV/IA) rtPA on clinical outcome in AIS.
  
  
  METHODS
  Recanalization was classified angiographically as complete (as compared with unoccluded vessel, thrombolysis in myocardial infarction classification [TIMI] 3), none (with no change from prethrombolysis, TIMI 0), and partial (when a change in the flow from baseline was noted, TIMI 1-2). Outcomes were symptomatic intracranial hemorrhage (sICH), 90-day modified Rankin scale (< or = 2 as a good outcome), and 3-month mortality.
  
  
  RESULTS
  Ninety-six patients had either combined IV/IA (41) or IA (55) rtPA for AIS during a 7-year period. Any recanalization occurred in 69%; 55% of those had a good outcome versus 23% in the rest (Odds ratio = 3.9; 95% confidence interval [CI] = 1.4-11.2; P = .007). Only 24% had complete recanalization; 74% had a good outcome versus 36% in the nonrecanalization group (OR = 5.1; 95% CI = 1.6-16.8; P = .002). When adjusted to time to therapy and vessel occluded, these results lessened but remained significant. The sICH rate with any recanalization was 7.6% versus 13.3% in patients with persistent clot (relative risk (RR) = 0.6; 95% CI = 0.2-2.0; P = .45). Death occurred in 19.7% of those whose vessels recanalized versus 33.3% in the rest (RR = 0.56; 95% = 0.26-1.19; P = .2).
  
  
  CONCLUSIONS
  A total of 24% and 69% of patients had complete and any recanalization, respectively, following endovascular rtPA therapy of AIS. The degree of recanalization was directly related to time to therapy and associated with good clinical outcome without an increase in the rate of adverse effect.
authors.affiliation: Department of Neurology, Case Western University Medical Center, Cleveland, OH, USA.
authors.forename: Osama O
authors.initials: OO
authors.lastname: Zaidat
authors.forename: Jose I
authors.initials: JI
authors.lastname: Suarez
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Sunshine
authors.forename: Robert W
authors.initials: RW
authors.lastname: Tarr
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Alexander
authors.forename: Tony P
authors.initials: TP
authors.lastname: Smith
authors.forename: David S
authors.initials: DS
authors.lastname: Enterline
authors.forename: Warren R
authors.initials: WR
authors.lastname: Selman
authors.forename: Dennis M D
authors.initials: DM
authors.lastname: Landis
mesh_terms: D000368:Aged; D015901:Angiography, Digital Subtraction; D002545:Brain Ischemia / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D020521:Stroke / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D016896:Treatment Outcome; D014654:Vascular Patency
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator